<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497367</url>
  </required_header>
  <id_info>
    <org_study_id>S2030</org_study_id>
    <secondary_id>S2030-FHU-2007</secondary_id>
    <nct_id>NCT00497367</nct_id>
  </id_info>
  <brief_title>Safety Study to Assess the Feasibility of Use in Humans of the TAXUS Petal Bifurcation Coronary Stent System</brief_title>
  <official_title>A Prospective, Single-arm, Multicenter 2-phase Feasibility Study to Assess the TAXUS Petal Paclitaxel-Eluting Bifurcation Coronary Stent System (TAXUS Petal)for the Treatment of de Novo Atherosclerotic Bifurcation Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and feasibility of use in humans of the&#xD;
      TAXUS Petal Paclitaxel-Eluting Bifurcation Coronary Stent System in the treatment of de novo&#xD;
      lesions in native coronary arteries involving a major side branch. The TAXUS® Petal™ is an&#xD;
      investigational device with an indication of improving coronary artery luminal diameter while&#xD;
      maintaining side branch access in subjects with symptomatic ischemic disease due to discrete&#xD;
      atherosclerotic bifurcation lesions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety and feasibility of use in humans of the TAXUS Petal Paclitaxel-Eluting&#xD;
      Bifurcation Coronary Stent System (TAXUS® Petal™) for the treatment of de novo&#xD;
      atherosclerotic bifurcation lesions (by visual estimate):&#xD;
&#xD;
        -  Phase 1:&#xD;
&#xD;
             -  Main branch: 3.0 to 3.5 mm RVD and lesion length ≤20 mm&#xD;
&#xD;
             -  Side branch: 2.5 to 3.5 mm RVD and lesion length ≤14 mm&#xD;
&#xD;
        -  Phase 2:&#xD;
&#xD;
             -  Main branch: 3.0 to 3.5 mm RVD and lesion length ≤28 mm&#xD;
&#xD;
             -  Side branch: 2.25 to 3.5 mm RVD and lesion length ≤14 mm&#xD;
&#xD;
      Bifurcation main branch (MB) lesion length will be measured from the proximal shoulder of the&#xD;
      most proximal lesion to the distal shoulder of the most distal lesion. Bifurcation side&#xD;
      branch (SB) lesion length will be measured from the proximal shoulder of the side branch (if&#xD;
      the ostium is disease-free) or the side branch ostium (if the disease continues into the main&#xD;
      branch) to the distal side branch shoulder of the most distal lesion. At follow-up, the&#xD;
      entire stented region will be used to determine MLD and %DS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite safety endpoint at 30 days post-procedure: • All-cause mortality • Documented myocardial infarction • TVR</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success Technical Success Clinical Procedural Success Device malfunctions Ease-of-Use parameters Clinical endpoints Main branch and side branch angiographic endpoints Main branch and side branch IVUS endpoints</measure>
    <time_frame>Index procedure, 30 days, 6 months and 1 - 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm received the TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Coronary Intervention (PCI) TAXUS Petal</intervention_name>
    <description>TAXUS Petal, paclitaxel eluting stent</description>
    <arm_group_label>TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - Phases 1 and 2&#xD;
&#xD;
          -  Age is ≥18 years old and ≤80 years old&#xD;
&#xD;
          -  Eligible for PCI&#xD;
&#xD;
          -  Acceptable candidate for CABG&#xD;
&#xD;
          -  Documented stable angina pectoris (CCS Classification 1, 2, 3, or 4) or unstable&#xD;
             angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C, or IIIB-C), or&#xD;
             documented silent ischemia&#xD;
&#xD;
          -  LVEF known to be ≥40%&#xD;
&#xD;
          -  Clinical angiographic success in non-target lesion (if a non-target lesion is treated)&#xD;
&#xD;
          -  Subject (or legal guardian) understands the study requirements and procedures and&#xD;
             provides written Informed Consent before any study tests or procedures are performed&#xD;
&#xD;
          -  Subject willing to comply with follow-up evaluations&#xD;
&#xD;
        Exclusion Criteria - Phases 1 and 2&#xD;
&#xD;
          -  Contraindication to ASA, or to Thienopyridine derivatives (e.g. Clopidogrel,&#xD;
             Ticlopidine)&#xD;
&#xD;
          -  High risk of bleeding&#xD;
&#xD;
          -  Known hypersensitivity to paclitaxel&#xD;
&#xD;
          -  Known allergy to stainless steel&#xD;
&#xD;
          -  Known allergy to platinum&#xD;
&#xD;
          -  Previous treatment of the target vessel with any anti-restenotic drug-coated or&#xD;
             drug-eluting coronary stent&#xD;
&#xD;
          -  Previous treatment of the target vessel with BMS within 9 months before index&#xD;
             procedure&#xD;
&#xD;
          -  Previous treatment of any non-target vessel with any anti-restenotic drug-coated or&#xD;
             DES within 9 months before index procedure&#xD;
&#xD;
          -  Previous treatment with intravascular brachytherapy in the target vessel&#xD;
&#xD;
          -  Planned PCI or CABG post-index procedure&#xD;
&#xD;
          -  Planned target vessel treatment with an unapproved device, directional or rotational&#xD;
             coronary atherectomy, laser, cutting balloon, or transluminal extraction catheter&#xD;
&#xD;
          -  Documented MI within 72 hours prior to index procedure&#xD;
&#xD;
          -  CK &gt; 2 x ULN + positive CK-MB OR&#xD;
&#xD;
          -  CK &gt; 2 x ULN + positive troponin OR&#xD;
&#xD;
          -  If no CK-MB or troponin was drawn, patients are excluded with CK &gt; 2xULN&#xD;
&#xD;
          -  As per protocol definitions found in Appendix A:&#xD;
&#xD;
          -  CVA within the past 6 months&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Acute or chronic renal dysfunction&#xD;
&#xD;
          -  Prior anaphylactic reaction to contrast agents&#xD;
&#xD;
          -  Leukopenia&#xD;
&#xD;
          -  Thrombocytopenia&#xD;
&#xD;
          -  Thrombocytosis&#xD;
&#xD;
          -  Active peptic ulcer or active GI bleeding&#xD;
&#xD;
          -  Current treatment, or past-treatment within 12 months of the index procedure, with&#xD;
             paclitaxel or other chemotherapeutic agents&#xD;
&#xD;
          -  Anticipated treatment with paclitaxel or oral rapamycin within 9 months of index&#xD;
             procedure&#xD;
&#xD;
          -  Subject's (men and women) known intention to procreate within 9 months of index&#xD;
             procedure&#xD;
&#xD;
          -  Positive pregnancy test or nursing an infant within 7 days prior to index procedure&#xD;
&#xD;
          -  Life expectancy of less than 24 months due to other medical conditions&#xD;
&#xD;
          -  Co-morbid condition(s) that could limit subject's ability to comply with study&#xD;
             follow-up or impact study scientific integrity&#xD;
&#xD;
          -  Currently participating in another investigational drug or device clinical study&#xD;
&#xD;
          -  Planned surgery at time of enrollment within the next 9 months after index procedure&#xD;
&#xD;
        Angiographic Inclusion Criteria - Phases 1 &amp; 2&#xD;
&#xD;
          -  Target Lesion (main and / or side branch):&#xD;
&#xD;
          -  located in native coronary artery&#xD;
&#xD;
          -  must be de novo&#xD;
&#xD;
          -  main branch %DS is ≥50% and &lt;100%&#xD;
&#xD;
          -  is a bifurcation lesion with an angle ≥30º and ≤90º&#xD;
&#xD;
          -  is enrolled after successful pre-dilatation of the target vessel&#xD;
&#xD;
        Angiographic Inclusion Criteria - Phase 1&#xD;
&#xD;
          -  Main branch of target lesion located in parent branch of LAD or LCx or RCA&#xD;
&#xD;
          -  Target lesion located in proximal or mid-section of vessel only (crux of RCA [distal&#xD;
             RCA] is allowed)&#xD;
&#xD;
          -  Main branch RVD ≥3.00 mm to ≤3.5 mm; lesion length ≤20 mm (to be covered by TAXUS®&#xD;
             Petal™ stent and maximum of 1 additional TAXUS stent ≤12 mm in length)&#xD;
&#xD;
          -  Side branch RVD ≥2.5 mm to ≤3.5 mm; lesion length ≤14 mm to be treated by maximum of 1&#xD;
             TAXUS stent ≤16 mm in length Angiographic Inclusion Criteria - Phase 2&#xD;
&#xD;
          -  Main branch of target lesion located in parent branch of LAD or LCx or RCA without&#xD;
             restrictions&#xD;
&#xD;
          -  Main branch RVD ≥3.00 mm to ≤3.5 mm; lesion length ≤28 mm (to be covered by TAXUS®&#xD;
             Petal™ stent and maximum of 1 additional TAXUS stent ≤20 mm in length)&#xD;
&#xD;
          -  Side branch RVD ≥2.25 mm to ≤3.5 mm; lesion length ≤14 mm to be treated by maximum of&#xD;
             1 TAXUS stent ≤16 mm in length&#xD;
&#xD;
        Angiographic Exclusion Criteria - Phases 1 &amp; 2&#xD;
&#xD;
          -  Target lesion located in left main (protected or unprotected)&#xD;
&#xD;
          -  Medina Classification 0.0.1&#xD;
&#xD;
          -  Target lesion is restenotic&#xD;
&#xD;
          -  Target lesion located in a SVG or mammary artery graft&#xD;
&#xD;
          -  Target lesion accessed via SVG or mammary artery graft&#xD;
&#xD;
          -  Target lesion is &lt;5 mm from BMS&#xD;
&#xD;
          -  Target lesion is &lt;5 mm from second side branch vessel ≥1.5 mm in diameter&#xD;
&#xD;
          -  Untreated lesions with ≥50% DS or thought to impair flow remaining in target vessel&#xD;
&#xD;
          -  Target lesion and/or vessel proximal to target lesion moderately or severely calcified&#xD;
&#xD;
          -  Target lesion and/or target vessel proximal to target lesion severely tortuous&#xD;
&#xD;
          -  Main branch target lesion located within or distal to a &gt;60° bend in target vessel&#xD;
&#xD;
          -  Target vessel with angiographic presence of probable or definite thrombus&#xD;
&#xD;
          -  Unprotected LM disease&#xD;
&#xD;
          -  Protected LM disease with target lesion in LAD or LCx (subject may be enrolled if only&#xD;
             lesion is target lesion in RCA)&#xD;
&#xD;
        Angiographic Exclusion Criteria&#xD;
&#xD;
          -  Phase 1: Target lesion TIMI flow &lt;3&#xD;
&#xD;
          -  Phase 2: Target lesion TIMI flow &lt;2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Ormiston, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Auckland City Hospital, Grafton, Auckland NZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Hospitalier Jacques Cartier-ICPS, 6, Avenue du Noyer Lambert</name>
      <address>
        <city>Massy</city>
        <zip>91349</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Siegburg, Ringstrasse 49</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Angiography Unit, 98 Mountain Road, First Floor</name>
      <address>
        <city>Auckland</city>
        <state>Epsom</state>
        <zip>1003</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital, Cardiac Investigations Unit, Park Road</name>
      <address>
        <city>Auckland</city>
        <state>Grafton</state>
        <zip>1030</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>July 4, 2007</study_first_submitted>
  <study_first_submitted_qc>July 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2007</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>feasibility</keyword>
  <keyword>bifurcation</keyword>
  <keyword>lesion</keyword>
  <keyword>de novo</keyword>
  <keyword>intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

